June 3, 2019
Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL
03.06.2019 07:00
Oslo, Norway 3 June 2019
Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company’s European...
Read more
Read more
June 3, 2019
Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
June 3, 2019
Press release - Non-regulatory
Combination of ONCOS-102 and Keytruda reduces size of non-injected tumors
In vivo proof-of-concept of ONC...
Read more
Read more
June 3, 2019
Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)
-Targeted antibody elicits responses in both FGFR3 wild-type and mutant/fusion patients-
-Favorable tolerability and safety profile and prolonged treatment duration-
- Results pr...
Read more
Read more
May 29, 2019
Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude
Sustained, clinically meaningful bilateral improvement in visual functions 96 weeks after injection
Observed bilateral improvement interpreted as clearly superior to known n...
Read more
Read more
May 23, 2019
Targovax to fully focus on ONCOS oncolytic virus program
Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announc...
Read more
Read more
May 23, 2019
Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announc...
Read more
Read more
May 23, 2019
Nordic Nanovector ASA – Results for the First Quarter 2019
Oslo, Norway, 23 May 2019
Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company’s senior management team ...
Read more
Read more
May 21, 2019
MIPS acquires patent rights and the brand FLUID
May 21, 2019
MIPS, the world leader in brain protection systems within helmet-based safety, has today entered into an acquisition agreement for assets that further enhan...
Read more
Read more
May 21, 2019
Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort
Oslo, Norway, 21 May 2019
Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial...
Read more
Read more
May 21, 2019
CERAMENT® – Now Available Exclusively Through BONESUPPORT
Boston, US, 09.30 ET, 21 May 2019 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, is now the exclusive distributor of CERAME...
Read more
Read more